Hovingh GK, Davidson MH, Kastelein JP, et al. Diagnosisand treatment of familial hypercholesterolaemia. Eur HeartJ 2013;34:962-71.
Srimahachota S, Kanjanavanich R, Boonyaratavej S, et al.Demographic, Management Practices and In-Hospital Outcomesof Thai Acute Coronary Syndrome Registry (TACSR):The different from the Western World. J Med Assoc Thai2007;90(Suppl 1):1-11.
Kositchaiwat J. Treatment outcome in Thai Acute CoronarySyndrome cases, 7R: Ways to reduce mortality in AcuteCoronary Syndrome, Veerakul G and Kositchaiwat J eds;Srinakorn Design Printing, Bangkok, ISBN 978-616-348-612- 7;2015:278-96.
Veerakul G, Khajornyai A, Wongkasai S et al. Predicting andPreventing Cardiovascular Events in Asymptomatic Patients:A 10-Year Prospective Study. BKK Med J 2017;13(1):1-12.
Veerakul G. The developmental standard guideline for treatingacute ST elevation myocardial infarction. Official researchdocument for graduating of the 39th Air War College, 2005,Royal Thai Air Force. (http://www.library.rtaf.mi.th.)
Tungsubutra W, Treesukosol D, Buddhari W, et al. Acutecoronary syndrome in young adults: the Thai ACS Registry.J Med Assoc Thai 2007;90(Suppl 1):81-90.
Chen TS, Incani A, Butler TC, et al. The demographic profileof young patients (
Ahmad T, Alam MB, Khan A, et al. Study on Risk Factorsand Pattern of Coronary Artery Involvement in Young AcuteCoronary Syndrome Patients. Bangladesh Heart J 2017; 32(1):40-4.
Pasricha A, Batchelor W. When young hearts are broken:Profiles of premature myocardial infarction. Am Heart J2002;143:4-6.
Wilson PW, D’Agostino RB, Levy D, et al. Prediction ofcoronary heart disease using risk factor categories. Circulation1998;97(18):1837-47.
World Health Organization (WHO). Prevention of CardiovascularDisease: Pocket Guidelines of Assessment and Managementof Cardiovascular Risk (WHO/ISH Cardiovascular Risk(WHO/ISH Cardiovascular Risk Prediction Charts for WHOepidemiological sub-regions AFR D and AFR E), Geneva2007. (Accessed January 7, 2017, at http://www.who.int/cardiovascular_diseases/guidelines/PocketGL.ENGLISH.AFR-D-E.rev1.pdf).
Williams RR, Hunt SC, Schumacher MC, et al. Diagnosingheterozygous familial hypercholesterolemia using newpractical criteria validated by molecular genetics. Am J Cardiol1993;72:171-6.
Scientific Steering Committee on behalf of the Simon BroomeRegister Group. Mortality in treated heterozygous familialhypercholesterolaemia: implications for clinical management.Atherosclerosis 1999;142:105-12.
Civeira F. Guidelines for the diagnosis and management ofheterozygous familial hypercholesterolemia. Atherosclerosis2004;173:55-68.
Austin MA, Hutter CM, Zimmern RL, et al. Familialhypercholesterol emia and coronary heart disease: a HuGEassociation review. Am J Epidemiol 2004;160:421-9.
Goldstein JL, Brown MS. History of Discovery: The LDLReceptor. Arterioscler Thromb Vasc Biol 2009;29(4):431-8.
Innerarity TL, Weisgraber KH, Arnold KS, et al. Familialdefective apolipoprotein B-100: low density lipoproteins withabnormal receptor binding. Proc Natl Acad Sci USA1987;84:6919-23.
Francke U, Brown MS, Goldstein JL. Assignment of thehuman gene for the low density lipoprotein receptor tochromosome 19: synteny of a receptor, a ligand, and agenetic disease. Proc Natl Acad Sci USA 1984;81:2826-30.
Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9cause autosomal dominant hypercholesterolemia. Nat Genet2003;34:154-6.
Goldberg AC, Hopkins PN, Toth PP, et al. Familialhypercholesterolemia: screening, diagnosis and managementof pediatric and adult patients: clinical guidance from theNational Lipid Association Expert Panel on FamilialHypercholesterolemia. J Clin Lipidol 2011;5:133-40.
Livy A, Lye SH. Familial hypercholesterolemia in Asia: AReview. OMIC Res 2011;1:22-31.
Jeenduang N, Ruangpracha A, Promptmas C, et al. Twonovel D151Y and M391T LDLR mutations causing LDLRtransport defects in Thai patients with familial hypercholesterolemia.Clin Chim Acta 2010;411(21-22):1656-61.
National Institute for Health and Clinical Excellence (NICE).Identification and management of familial hypercholesterolaemia.2008. (Accessed January 8, 2017, at https://www.nice.org.uk/guidance/cg71/documents/familial-hypercholesterolaemianice-guideline2).
Reiner Z, Catapano AL, De Backer G, et al. The ESC/EASGuidelines for the management of dyslipidaemias: the TaskForce for the management of dyslipidaemias of the EuropeanSociety of Cardiology (ESC) and the European AtherosclerosisSociety (EAS). Eur Heart J 2011;32:1769-818.
Grundy SM, Cleeman JI, Merz CN, et al. Implications ofrecent clinical trials for the National Cholesterol EducationProgram Adult Treatment Panel III Guide- lines. J Am CollCardiol 2004;44:720-32.
Genest J, McPherson R, Frohlich J, et al. 2009 CanadianCardiovascular Society/Canadian guidelines for the diagnosisand treatment of dyslipidemia and prevention of cardiovasculardisease in the adult – 2009 recommendations. Can J Cardiol2009;25:567-79.
2016 European Guidelines on cardiovascular disease preventionin clinical practice; The Sixth Joint Task Force of theEuropean Society of Cardiology and Other Societies onCardiovascular Disease Prevention in Clinical Practice. EurHeart J 2016;37:2315-81.
Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia:summary of NICE guidance. BMJ2008;337:a1095.
Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacyof statins in familial hypercholesterolaemia: a long term cohortstudy. BMJ 2008;337:a2423.
